Justin Pritchard

Huck Early Career Entrepreneurial Professorship; Assistant Professor of Biomedical Engineering;

212 Wartik Lab
University Park, PA
jrp94@psu.edu
814-865-7906

Research Summary

Using systems and synthetic biology approaches to understand and control drug resistance.

Huck Graduate Students

Huck Affiliations

Center for Mathematical Biology

Molecular, Cellular, and Integrative Biosciences

Center for Structural Oncology

Integrative and Biomedical Physiology

Publication Tags

Genome Neoplasms Pharmaceutical Preparations Genes Growth Therapeutics Mutation Mycobacterium Platinum Clustered Regularly Interspaced Short Palindromic Repeats Sars Virus Drug Oxaliplatin Cisplatin Drug Combinations Vibrio Cholerae Infections Population Datasets Epidemics Lymphoma Tumors Mycobacterium Tuberculosis Biomarkers Synthetic Lethal Mutations

Most Recent Publications

Genomic and experimental evidence that alternate transcription initiation of the Anaplastic Lymphoma Kinase (ALK) kinase domain does not predict single agent sensitivity to

Haider Inam*, Ivan Sokirniy*, Yiyun Rao*, Anushka Shah*, Farnaz Naeemikia*, Edward O'Brien, Cheng Dong, Justin Pritchard, iScience on p. 21

The risks of perpetuating an evolutionary arms race in drug discovery

Scott Leighow*, Justin Pritchard, Evolution, Medicine, and Public Health

A pan-CRISPR analysis of mammalian cell specificity identifies ultra-compact sgRNA subsets for genome-scale experiments

Boyang Zhao, Yiyun Rao, Scott Leighow, Edward P. O’Brien, Luke Gilbert, Justin R. Pritchard, 2022, Nature Communications

SARS-CoV-2 Attack Rate and Population Immunity in Southern New England, March 2020 to May 2021

Thu Nguyen Anh Tran, Nathan B. Wikle, Fuhan Yang, Haider Inam, Scott Leighow, Bethany Gentilesco, Philip Chan, Emmy Albert, Emily R. Strong, Justin R. Pritchard, William P. Hanage, Ephraim M. Hanks, Forrest W. Crawford, Maciej F. Boni, 2022, JAMA network open on p. E2214171

Phase II Study of Ponatinib in Advanced Gastrointestinal Stromal Tumors: Efficacy, Safety, and Impact of Liquid Biopsy and Other Biomarkers

Suzanne George, Margaret von Mehren, Jonathan A. Fletcher, Jichao Sun, Sen Zhang, Justin R. Pritchard, John Graeme Hodgson, David Kerstein, Victor M. Rivera, Frank G. Haluska, Michael C. Heinrich, 2022, Clinical Cancer Research on p. 1268-1276

Self-assembled ruthenium and osmium nanosystems display a potent anticancer profile by interfering with metabolic activity

Mickaël Marloye, Haider Inam, Connor J. Moore, Tyler R. Mertens, Aude Ingels, Marilin Koch, Michal O. Nowicki, Véronique Mathieu, Justin R. Pritchard, Samuel G. Awuah, Sean E. Lawler, Franck Meyer, François Dufrasne, Gilles Berger, 2022, Inorganic Chemistry Frontiers

SARS-CoV-2 epidemic after social and economic reopening in three U.S. states reveals shifts in age structure and clinical characteristics

Nathan B. Wikle, Thu Tran, Thu Nguyen-Anh Tran, Emily Strong, Bethany Gentilesco, Ephraim Hanks, Scott M. Leighow, Emmy Albert, Emily R. Strong, Karel Brinda, Haider Inam, Fuhan Yang, Sajid Hossain, Philip Chan, William P. Hanage, Maria Messick, Justin R. Pritchard, Maciej F. Boni, 2022, Science advances on p. eabf9868

Materials-driven approaches to understand extrinsic drug resistance in cancer

Justin R. Pritchard, Michael J. Lee, Shelly R. Peyton, 2022, Soft Matter

A global cancer data integrator reveals principles of synthetic lethality, sex disparity and immunotherapy

Christopher Yogodzinski, Abolfazl Arab, Justin R. Pritchard, Hani Goodarzi, Luke A. Gilbert, 2021, Genome Medicine

Genomic and experimental evidence that ALK<sup>ATI</sup> does not predict single agent sensitivity to ALK inhibitors

Haider Inam, Ivan Sokirniy, Yiyun Rao, Anushka Shah, Farnaz Naeemikia, Edward O'Brien, Cheng Dong, David M. McCandlish, Justin R. Pritchard, 2021, iScience

Most-Cited Papers

A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress

Peter M. Bruno, Yunpeng Liu, Ga Young Park, Junko Murai, Catherine E. Koch, Timothy J. Eisen, Justin R. Pritchard, Yves Pommier, Stephen J. Lippard, Michael T. Hemann, 2017, Nature Medicine on p. 461-471

Programmable transcriptional repression in mycobacteria using an orthogonal CRISPR interference platform

Jeremy M. Rock, Forrest F. Hopkins, Alejandro Chavez, Marieme Diallo, Michael R. Chase, Elias R. Gerrick, Justin R. Pritchard, George M. Church, Eric J. Rubin, Christopher M. Sassetti, Dirk Schnappinger, Sarah M. Fortune, 2017, Nature Microbiology

Defining principles of combination drug mechanisms of action

Justin R. Pritchard, Peter M. Bruno, Luke A. Gilberta, Kelsey L. Caprona, Douglas A. Lauffenburger, Michael T. Hemann, 2013, Proceedings of the National Academy of Sciences of the United States of America on p. E170-E179

ARTIST: High-Resolution Genome-Wide Assessment of Fitness Using Transposon-Insertion Sequencing

Justin R. Pritchard, Michael C. Chao, Sören Abel, Brigid M. Davis, Catherine Baranowski, Yanjia J. Zhang, Eric J. Rubin, Matthew K. Waldor, 2014, PLoS Genetics on p. e1004782

High-resolution definition of the Vibrio cholerae essential gene set with hidden Markov model-based analyses of transposon-insertion sequencing data

Michael C. Chao, Justin R. Pritchard, Yanjia J. Zhang, Eric J. Rubin, Jonathan Livny, Brigid M. Davis, Matthew K. Waldor, 2013, Nucleic Acids Research on p. 9033-9048

Addressing genetic tumor heterogeneity through computationally predictive combination therapy

Boyang Zhao, Justin R. Pritchard, Douglas A. Lauffenburger, Michael T. Hemann, 2014, Cancer Discovery on p. 166-174

Exploiting Temporal Collateral Sensitivity in Tumor Clonal Evolution

Boyang Zhao, Joseph C. Sedlak, Raja Srinivas, Pau Creixell, Justin R. Pritchard, Bruce Tidor, Douglas A. Lauffenburger, Michael T. Hemann, 2016, Cell on p. 234-246

Identification of genes required for Mycobacterium abscessus growth in vivo with a prominent role of the ESX-4 locus

Laura Laencina, Violaine Dubois, Vincent Le Moigne, Albertus Viljoen, Laleh Majlessi, Justin Pritchard, Audrey Bernut, Laura Piel, Anne Laure Roux, Jean Louis Gaillard, Bérengère Lombard, Damarys Loew, Eric J. Rubin, Roland Brosch, Laurent Kremer, Jean Louis Herrmann, Fabienne Girard-Misguich, 2018, Proceedings of the National Academy of Sciences of the United States of America on p. E1002-E1011

The primary mechanism of cytotoxicity of the chemotherapeutic agent CX-5461 is topoisomerase II poisoning

Peter M. Bruno, Mengrou Lu, Kady A. Dennis, Haider Inam, Connor J. Moore, John Sheehe, Stephen J. Elledge, Michael T. Hemann, Justin R. Pritchard, 2020, Proceedings of the National Academy of Sciences of the United States of America on p. 4053-4060

Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors

Theresa Baker, Sujata Nerle, Justin Pritchard, Boyang Zhao, Victor M. Rivera, Andrew Garner, Francois Gonzalvez, 2015, Oncotarget on p. 32646-32655

News Articles Featuring Justin Pritchard

Feb 10, 2021

Researchers awarded $1.5M to create stem cell predictive model

Stem cells are the building blocks of the body, according to Penn State researchers. Though similar to one another at their origins, stem cells take on unique characteristics as they mature, becoming specialized cells throughout the body — such as bone, muscle, ligament, tissue or other organ cells.

Full Article

Mar 24, 2020

Engineers model mutations causing drug resistance

Whether it is a drug-resistant strain of bacteria, or cancer cells that no longer react to the drugs intended to kill them, diverse mutations make cells resistant to chemicals, and "second generation" approaches are needed. Now, a team of Penn State engineers may have a way to predict which mutations will occur in people, creating an easier path to create effective pharmaceuticals.